Certification allows the Company to begin to
supply medical cannabis across the European Union
First shipment expected to occur in fourth
quarter
LEAMINGTON, ON, Jan. 21, 2020 /PRNewswire/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APHA and NYSE:
APHA) today announced that it has received its European Union Good
Manufacturing Practices ("EU GMP") certification in respect
of medicinal products for human use and investigational medicinal
products for human use, from the Malta Medicines Authority
("MMA") at the Company's subsidiary, ARA - Avanti Rx
Analytics.
Aphria selected the MMA to perform the EU GMP audit as the
criteria and certification thresholds established by the MMA are
among the most stringent and demanding in the EU. The certification
will allow the Company to ship bulk and finished dried flower, as
well as bulk and finished cannabis oil for medicinal use in
permitted jurisdictions throughout the European Union.
"We believe that this is a game changer for Aphria Inc. and will
significantly advance our leadership in permissible medical
cannabis markets across Europe,
where demand for product is strong," said Irwin D. Simon, Chief Executive Officer. "With
2.4 million square feet of licensed production capacity of up to
255,000 kilograms, state-of-the-art greenhouses and labs, and our
global infrastructure, we believe Aphria is well positioned to lead
in the Canadian and international markets."
Aphria's German operations have been preparing for the
importation of EU-GMP certified cannabis from Canada, allowing for shipments to the
Company's German subsidiary CC Pharma GmbH ("CC Pharma") in
order to leverage CC Pharma's expansive in-country distribution
network. The Company anticipates that its first shipments of
medical cannabis to CC Pharma will occur in its fourth quarter of
its fiscal 2020.
We Have A Good Thing Growing
About Aphria Inc.
Aphria Inc. is a leading global
cannabis company driven by an unrelenting commitment to our people,
the planet, product quality and innovation. Headquartered in
Leamington, Ontario – the
greenhouse capital of Canada –
Aphria Inc. has been setting the standard for the low-cost
production of high-quality cannabis at scale, grown in the most
natural conditions possible. Focusing on untapped opportunities and
backed by the latest technologies, Aphria Inc. is committed to
bringing breakthrough innovation to the global cannabis market. The
Company's portfolio of brands is grounded in expertly-researched
consumer insights designed to meet the needs of every consumer
segment. Rooted in our founders' multi-generational expertise in
commercial agriculture, Aphria Inc. drives sustainable long-term
shareholder value through a diversified approach to innovation,
strategic partnerships and global expansion.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "will", "should", "anticipate", "expect", "potential",
"believe", "intend" or the negative of these terms and similar
expressions. Forward-looking statements in this news release
include, but are not limited to, statements with respect to the
expected impact of the EU GMP certification on the Company's
business and expectations related to the Company's market position.
Forward-looking statements necessarily involve known and unknown
risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; marketing costs; loss
of markets; future legislative and regulatory developments
involving cannabis; inability to access sufficient capital from
internal and external sources, and/or inability to access
sufficient capital on favourable terms; the cannabis industry in
Canada generally, income tax and
regulatory matters; the ability of Aphria Inc. to implement its
business strategies; competition; crop failure; currency and
interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive
and should carefully review the various risks and uncertainties
identified in the Company's filings on SEDAR and EDGAR. Readers are
further cautioned not to place undue reliance on forward-looking
statements as there can be no assurance that the plans, intentions
or expectations upon which they are placed will occur. Such
information, although considered reasonable by management at the
time of preparation, may prove to be incorrect and actual results
may differ materially from those anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aphria-inc-receives-eu-gmp-certification-for-subsidiary-ara-avanti-rx-analytics-300990203.html
SOURCE Aphria Inc.